UP!

CRY $16.69   View long term graphs

CryoLife, Inc.
Type
Public
Traded as NYSE: CRY
S&P 600 Component
Founded 1984
Founder Steve Anderson
Headquarters Kennesaw, Georgia, United States
Key people
J. Patrick Mackin, Chairman of the Board, President & CEO
Products human tissues for transplant, medical devices
Revenue $146 million (2015)
Number of employees
435 (2008)
Website www.cryolife.com

CryoLife, Inc. is a distributor of cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. Among its products are human heart valves, which are treated to remove excess cellular material and antigens, and BioGlue surgical adhesive.

CryoLife, Inc. incorporated in 1984 in Florida, was the first biomedical company to specialize in the ultra-low temperature preservation of human heart valves used for cardiac reconstruction, primarily in children born with heart defects. The Company preserves and distributes human tissues and develops, manufactures, and commercializes medical devices for cardiac and vascular transplant applications. The human tissues distributed by CryoLife include the CryoValve® SG pulmonary human heart valve and the CryoPatch® SG pulmonary cardiac patch tissue, both processed using CryoLife’s proprietary SynerGraft® technology. CryoLife’s medical devices consist primarily of surgical adhesives, sealants, and hemostats including BioGlue® Surgical Adhesive, BioFoam® Surgical Matrix, PerClot®, which the Company began distributing for Starch Medical, Inc. in October 2010.

The Company preserves small diameter human saphenous vein conduits (3mm to 6mm) for use in peripheral vascular reconstructions and coronary bypass surgery. Failure to achieve revascularization of an obstructed vessel may result in the loss of a limb or even death of the patient. When patients require bypass surgery, the surgeon’s first choice generally is the patient’s own vein tissue. However, in cases of advanced vascular disease, 30% of patients have unsuitable vein tissue for transplantation, and the surgeon must consider using synthetic grafts or preserved human vascular tissue. Small diameter synthetic vascular grafts are generally not optimal for below-the-knee surgeries because they have a tendency to obstruct over time. Preserved human vascular tissues tend to remain open longer and as such are used in indications where synthetics typically fail. In addition, synthetic grafts are not suitable for use in infected areas since they may harbor bacteria and are difficult to treat with antibiotics. Preserved human vascular tissues are ideal grafts for patients with previously infected graft sites. The Company also preserves femoral veins and arteries and aortoiliac arteries for bypass or reconstruction within infected surgical areas.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-02-11 Future report Set alerts
Q3 2020 2020-10-28 Future report Set alerts
Q2 2020 2020-07-30 -0.02 -0.10
Q1 2020 2020-04-30 -0.08 -0.18
Q4 2019 2020-02-13 0.10 -0.02
Q3 2019 2019-10-30 0.06 0.00
Q2 2019 2019-07-30 0.11 0.07
Q1 2019 2019-04-30 0.04 -0.01
Q4 2018 2019-02-13 0.05 -0.02
Q3 2018 2018-10-31 0.08 0.04

Ratings

2016-06-20 Reiterated Rating Canaccord Genuity Buy
2016-06-15 Initiated Coverage Lake Street Capital Buy $15.00
2016-04-28 Downgrade Ladenburg Thalmann Buy to Neutral $12.00
2016-04-21 Reiterated Rating Piper Jaffray Overweight $15.00
2016-04-21 Reiterated Rating Piper Jaffray Cos. Overweight $15.00
2016-04-13 Initiated Coverage Canaccord Genuity Buy $14.00
2015-12-30 Reiterated Rating Piper Jaffray Buy
2015-12-24 Reiterated Rating Piper Jaffray Overweight $15.00
2015-05-18 Initiated Coverage First Analysis Overweight $14.00
2015-01-02 Upgrade Piper Jaffray Neutral to Overweight $15.00
2014-12-23 Upgrade Piper Jaffray Neutral to Overweight $10.00 to $15.00
2012-04-24 Initiated Ladenburg Thalmann Buy $7.75
2011-07-29 Upgrade The Benchmark Company Hold to Buy $6.50
2011-04-29 Downgrade The Benchmark Company Buy to Hold $7 to $6.50
2010-07-23 Initiated The Benchmark Company Buy $8
2008-08-01 Reiterated Jesup & Lamont Buy $14 to $16.50
2008-05-15 Reiterated Roth Capital Buy $12 to $14
2008-03-31 Initiated Roth Capital Buy $12
2008-03-18 Initiated Jesup & Lamont Buy $14
2007-05-02 Upgrade Piper Jaffray Market Perform to Outperform
2016-06-20 Reiterated Rating Canaccord Genuity Buy
2016-06-15 Initiated Coverage Lake Street Capital Buy $15.00
2016-04-28 Downgrade Ladenburg Thalmann Buy to Neutral $12.00
2016-04-21 Reiterated Rating Piper Jaffray Overweight $15.00
2016-04-21 Reiterated Rating Piper Jaffray Cos. Overweight $15.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
ANDERSON STEVEN G President, CEO and Chairman 4.55%  (1271846) CRY /
Mackin James P President & CEO 1.26%  (351095) CRY /
LEE DAVID ASHLEY Exec. VP, COO and CFO 1.07%  (300079) CRY /
McCall Ronald D 0.52%  (146511) CRY /
Capps Scott B VP-Clinical Research 0.50%  (139087) CRY /
FRONK DAVID VP Reg. Affrs. and Qual Assur. 0.40%  (110559) CRY /
Horton Amy Chief Accounting Officer 0.37%  (102959) CRY /
ACKERMAN THOMAS F 0.36%  (99349) CRL / CRY /
BEVEVINO DANIEL J 0.36%  (99349) CRY /
RONALD C ELKINS 0.35%  (97849) CRY /
Burris Jeffrey W Vice President & Gen. Counsel 0.34%  (95221) CRY /
Salveson Jon W 0.28%  (79349) CRY / SSH /
Gale David C VP-Research and Development 0.28%  (77135) CRY /
Lang David P. Sr. VP, Intl Sales & Marketing 0.25%  (68441) CRY /
Holloway Jean F VP, General Counsel 0.21%  (57877) CRY /
Benson James 0.19%  (54086) CRY /
Davis John E Senior VP, Global Sales 0.18%  (51438) CRY /
Anderson Bruce G. VP, US Sales and Marketing 0.15%  (42106) CRY /
MORGAN HARVEY 0.15%  (40667) CRY / CYB / FDO /
Matthews William Robert Senior VP, Operations, Quality 0.14%  (39883) CRY /
McDermid James M SVP, CHRO 0.08%  (21339) CRY /
Bullock James 0.03%  (8266) CRY /
Saurini Sherry M VP, Quality 0.02%  (5294) CRY /

Comments